Safety and efficacy of an oral piperidine-based, reversible inhibitor of acetylcholinesterase in client-owned dogs
Study title: Safety and efficacy of an oral piperidine-based, reversible inhibitor of acetylcholinesterase in client-owned dogs with allergic skin disease
Current Status: Active and enrolling
Principal Investigator: Sheila Torres, DVM, MS, PhD, DACVD, [email protected], 612-625-3715
Contact: Andrea Chehadeh, Senior Research Study Technician, [email protected], 612-625-3157
The purpose of this clinical study is to show the effectiveness and safety of an oral medication in reducing the itch and inflammation associated with allergic dermatitis. All dogs will receive the same new oral capsule treatment.
- Dogs one year or older, weighing 6.6 – 176 pounds
- Non-seasonal signs of allergic dermatitis
- Dogs may continue on certain medications for the treatment of the allergic disease provided they continue to show clinical signs, and their medications have been in place for at least 8 weeks and will not change during the study.
- Dogs that are otherwise healthy, with no active infections
- Certain medications will require a withdrawal period.
- Other criteria apply, please contact us for details.
Each dog will complete 3 visits to the Veterinary Medical Center (VMC) in a 14-day study period for exams, assessments, and sample collection (blood and urine). Owners will give the study drug at home twice daily by mouth during the 14 days and will record observations daily.
Cost of the study:
The study will cover the costs of all study visits listed above. Upon completion, owners will be eligible for a debit card for their participation.
To learn more or to enroll, please contact Andrea Chehadeh or Dr. Torres (above).